Napatree Capital LLC Purchases Shares of 29,854 Organon & Co. (NYSE:OGN)

Napatree Capital LLC purchased a new stake in Organon & Co. (NYSE:OGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 29,854 shares of the company’s stock, valued at approximately $445,000.

Other hedge funds have also recently bought and sold shares of the company. Prospera Private Wealth LLC bought a new stake in Organon & Co. in the 3rd quarter valued at $25,000. Horizon Bancorp Inc. IN boosted its holdings in Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares during the period. Millstone Evans Group LLC bought a new stake in Organon & Co. in the 4th quarter valued at $29,000. Larson Financial Group LLC boosted its holdings in Organon & Co. by 345.4% in the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock valued at $33,000 after purchasing an additional 1,734 shares during the period. Finally, Riverview Trust Co boosted its holdings in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after purchasing an additional 1,292 shares during the period. 77.43% of the stock is owned by institutional investors.

Organon & Co. Trading Down 1.7 %

Shares of Organon & Co. stock opened at $15.33 on Friday. The stock has a market capitalization of $3.95 billion, a P/E ratio of 4.60, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The company has a 50-day simple moving average of $15.44 and a 200 day simple moving average of $16.45. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Research analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.31%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.’s payout ratio is presently 33.63%.

Analysts Set New Price Targets

A number of research firms have recently commented on OGN. Morgan Stanley reduced their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.